179 related articles for article (PubMed ID: 37093316)
1. Classification of triple-negative breast cancer based on pathway enrichment levels.
Liu Q; Wang X
Med Oncol; 2023 Apr; 40(6):157. PubMed ID: 37093316
[TBL] [Abstract][Full Text] [Related]
2. Subtyping of sarcomas based on pathway enrichment scores in bulk and single cell transcriptomes.
Li S; Liu Q; Zhou H; Lu H; Wang X
J Transl Med; 2022 Jan; 20(1):48. PubMed ID: 35093080
[TBL] [Abstract][Full Text] [Related]
3. Identification of Breast Cancer Immune Subtypes by Analyzing Bulk Tumor and Single Cell Transcriptomes.
Yao J; Li S; Wang X
Front Cell Dev Biol; 2021; 9():781848. PubMed ID: 35047498
[No Abstract] [Full Text] [Related]
4. Single-cell atlas reveals a distinct immune profile fostered by T cell-B cell crosstalk in triple negative breast cancer.
Ding S; Qiao N; Zhu Q; Tong Y; Wang S; Chen X; Tian Q; Xiao Y; Shen K
Cancer Commun (Lond); 2023 Jun; 43(6):661-684. PubMed ID: 37158690
[TBL] [Abstract][Full Text] [Related]
5. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer.
Guo S; Liu X; Zhang J; Huang Z; Ye P; Shi J; Stalin A; Wu C; Lu S; Zhang F; Gao Y; Jin Z; Tao X; Huang J; Zhai Y; Shi R; Guo F; Zhou W; Wu J
Comput Biol Med; 2023 Jul; 161():107066. PubMed ID: 37263064
[TBL] [Abstract][Full Text] [Related]
6. Identification of prostate cancer subtypes based on immune signature scores in bulk and single-cell transcriptomes.
Chen C; Luo J; Wang X
Med Oncol; 2022 Jun; 39(9):123. PubMed ID: 35716212
[TBL] [Abstract][Full Text] [Related]
7. Classification of triple-negative breast cancers based on Immunogenomic profiling.
He Y; Jiang Z; Chen C; Wang X
J Exp Clin Cancer Res; 2018 Dec; 37(1):327. PubMed ID: 30594216
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
[TBL] [Abstract][Full Text] [Related]
9. Identification of gastric cancer subtypes based on pathway clustering.
Li L; Wang X
NPJ Precis Oncol; 2021 Jun; 5(1):46. PubMed ID: 34079012
[TBL] [Abstract][Full Text] [Related]
10. Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach.
Bareche Y; Buisseret L; Gruosso T; Girard E; Venet D; Dupont F; Desmedt C; Larsimont D; Park M; Rothé F; Stagg J; Sotiriou C
J Natl Cancer Inst; 2020 Jul; 112(7):708-719. PubMed ID: 31665482
[TBL] [Abstract][Full Text] [Related]
11. Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy.
Zhou Y; Che Y; Fu Z; Zhang H; Wu H
Front Public Health; 2022; 10():902378. PubMed ID: 35875026
[TBL] [Abstract][Full Text] [Related]
12. Single-Cell Transcriptome Analysis Revealed Heterogeneity and Identified Novel Therapeutic Targets for Breast Cancer Subtypes.
Vishnubalaji R; Alajez NM
Cells; 2023 Apr; 12(8):. PubMed ID: 37190091
[TBL] [Abstract][Full Text] [Related]
13. Age-related mutational signature negatively associated with immune activity and survival outcome in triple-negative breast cancer.
Chen H; Chong W; Yang X; Zhang Y; Sang S; Li X; Lu M
Oncoimmunology; 2020 Jun; 9(1):1788252. PubMed ID: 32923150
[TBL] [Abstract][Full Text] [Related]
14. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
[TBL] [Abstract][Full Text] [Related]
15. Subtyping of head and neck squamous cell cancers based on immune signatures.
Song D; Lyu H; Feng Q; Luo J; Li L; Wang X
Int Immunopharmacol; 2021 Oct; 99():108007. PubMed ID: 34332341
[TBL] [Abstract][Full Text] [Related]
16. Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low.
Hu XE; Yang P; Chen S; Wei G; Yuan L; Yang Z; Gong L; He L; Yang L; Peng S; Dong Y; He X; Bao G
Breast Cancer Res; 2023 Mar; 25(1):34. PubMed ID: 36998014
[TBL] [Abstract][Full Text] [Related]
17. Essential amino acid metabolism-related molecular classification in triple-negative breast cancer.
Zhao Y; Pu C; Jiao D; Zhu J; Guo X; Liu Z
Epigenomics; 2021 Aug; 13(16):1247-1268. PubMed ID: 34448400
[TBL] [Abstract][Full Text] [Related]
18. Tumor microenvironment characterization in triple-negative breast cancer identifies prognostic gene signature.
Qin Y; Deng J; Zhang L; Yuan J; Yang H; Li Q
Aging (Albany NY); 2021 Feb; 13(4):5485-5505. PubMed ID: 33536349
[TBL] [Abstract][Full Text] [Related]
19. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC.
Bao X; Shi R; Zhao T; Wang Y; Anastasov N; Rosemann M; Fang W
Cancer Immunol Immunother; 2021 Jan; 70(1):189-202. PubMed ID: 32681241
[TBL] [Abstract][Full Text] [Related]
20. Genomic Characteristics of Triple-Negative Breast Cancer Nominate Molecular Subtypes That Predict Chemotherapy Response.
Kim J; Yu D; Kwon Y; Lee KS; Sim SH; Kong SY; Lee ES; Park IH; Park C
Mol Cancer Res; 2020 Feb; 18(2):253-263. PubMed ID: 31704731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]